Skip to main content

Advertisement

SpringerLink
Log in

Up-regulation of flotillin-2 is associated with renal cell carcinoma progression

  • Research Article
  • Published:
Tumor Biology

Abstract

Flotillin-2 (FLOT2) is a highly conserved protein isolated from caveolae/lipid raft domains that tether growth factor receptors linked to signal transduction pathway. FLOT2 has recently been identified to be involved in tumorigenesis of several cancers such as breast cancer, melanoma, and gastric cancer. However, the role of FLOT2 in renal cell carcinoma (RCC) remains unclear. The expression levels of FLOT2 in RCC patients and renal cancer cell lines were evaluated by quantitative real-time PCR (qRT-PCR) and Western blot. FLOT2 protein expression was also analyzed in archived paraffin-embedded RCC tissues using immunohistochemistry (IHC), and its association with overall survival of patients was analyzed by statistical analysis. Small-interfering RNA (siRNA) was used to suppress FLOT2 expression in RCC cell lines. In vitro assays were performed to further explore its role in tumor progression. The expression level of FLOT2 was higher in RCC tissues and cell lines than in corresponding adjacent normal tissues and normal human proximal tubule epithelial cell line HK-2. IHC analysis revealed high expression levels of FLOT2 in RCC specimens. The RCC patients with higher FLOT2 expression had an advanced clinical stage and poorer prognosis than those with lower FLOT2 expression. FLOT2 expression was an independent prognostic marker of overall RCC patient survival in a multivariate analysis. In vitro assays indicated that knockdown of FLOT2 reduced cell proliferation, migration, and invasion. Our data suggest that FLOT2 is a novel molecule involved in RCC progression, which provide a potential prognostic biomarker and therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.

    Article  CAS  PubMed  Google Scholar 

  2. Yang FQ, Yang FP, Li W, et al. Foxl1 inhibits tumor invasion and predicts outcome in human renal cancer. Int J Cli Exp Pathol. 2014;7(1):110.

    Google Scholar 

  3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398–406.

    Article  PubMed  Google Scholar 

  4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90.

    Article  CAS  PubMed  Google Scholar 

  5. Hollingsworth JM, Miller DC, Daignault S, et al. Five‐year survival after surgical treatment for kidney cancer. Cancer. 2007;109(9):1763–8.

    Article  PubMed  Google Scholar 

  6. Babuke T, Tikkanen R. Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol. 2007;86(9):525–32.

    Article  CAS  PubMed  Google Scholar 

  7. Staubach S, Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteome. 2011;8(2):263–77.

    Article  CAS  Google Scholar 

  8. Márquez DC, Chen HW, Curran EM, et al. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006;246(1):91–100.

    Article  PubMed  Google Scholar 

  9. Banning A, Kurrle N, Meister M, et al. Flotillins in receptor tyrosine kinase signaling and cancer. Cells. 2014;3(1):129–49.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    Article  CAS  PubMed  Google Scholar 

  11. Hazarika P, McCarty MF, Prieto VG, et al. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004;64(20):7361–9.

    Article  CAS  PubMed  Google Scholar 

  12. Berger T, Ueda T, Arpaia E, et al. Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model. Oncogene, 2012

  13. Wang X, Yang Q, Guo L, et al. Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 2013;11(1):190.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Cheng YX, Hu M, Chen L, et al. The mechanism of lipid raft mediating chemoresistance of cervical cancer. Saudi Med J. 2012;33(5):508–14.

    PubMed  Google Scholar 

  15. George KS, Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol. 2012;259(3):311–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Ji H, Greening DW, Barnes TW, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13(10–11):1672–86.

    Article  CAS  PubMed  Google Scholar 

  17. Cao K, Xie D, Cao P, et al. SiRNA-mediated flotillin-2 (Flot2) downregulation inhibits cell proliferation, migration, and invasion in gastric carcinoma cells. Oncol Res Featuring Preclinical Clin Cancer Ther. 2014;21(5):271–9.

    Article  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, No 301, Yanchang Mid-Road, Shanghai, 200072, China

    Yang Yan, Feng-qiang Yang, Hai-min Zhang, Jianping Che & Jun-hua Zheng

Authors
  1. Yang Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng-qiang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hai-min Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianping Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun-hua Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun-hua Zheng.

Additional information

Yang Yan, Feng-qiang Yang, and Hai-min Zhang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, Y., Yang, Fq., Zhang, Hm. et al. Up-regulation of flotillin-2 is associated with renal cell carcinoma progression. Tumor Biol. 35, 10479–10486 (2014). https://doi.org/10.1007/s13277-014-2343-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2343-9

Keywords

Search

Navigation